Clinical Trials Logo

Lymphoma, Follicular clinical trials

View clinical trials related to Lymphoma, Follicular.

Filter by:

NCT ID: NCT04998669 Recruiting - Follicular Lymphoma Clinical Trials

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Start date: February 11, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.

NCT ID: NCT04989621 Recruiting - Follicular Lymphoma Clinical Trials

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

Start date: August 1, 2021
Phase: Phase 2
Study type: Interventional

This phase 2 trial studies the efficacy and safety of orelabrutinib plus rituximab followed by maintenance with orelabrutinib for relapsed and refractory follicular lymphoma(RR FL)

NCT ID: NCT04982471 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

Start date: November 5, 2021
Phase:
Study type: Observational [Patient Registry]

The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, participant-level data longitudinally in participants diagnosed with various subtypes of non-Hodgkin lymphoma (NHL).

NCT ID: NCT04934930 Recruiting - Follicular Lymphoma Clinical Trials

Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status

FLMRD
Start date: January 29, 2020
Phase: Phase 2
Study type: Interventional

Follicular lymphoma (FL) is a chronic indolent malignancy, where treatment with 6 cycles of bendamustine obinutuzumab (BO) is highly effective but at a cost of increased adverse events. Tumor specific DNA can be traced in blood and bone marrow of follicular lymphoma patients even after therapy, and when detected after lymphoma treatment it is referred to as minimal residual disease (MRD). MRD elimination after effective lymphoma treatment is a marker for deep response and correlates with prolonged remission. In this study we aim to omit chemotherapy after 4 cycles of treatment in patients achieving MRD elimination after 3 months of therapy, as well as complete metabolic response on positron emission computed tomography (PET-CT), hoping to preserve treatment effectiveness while reducing adverse events.

NCT ID: NCT04903197 Recruiting - Clinical trials for Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Start date: January 24, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of VAY736 alone or in combination with other therapies in patients with NHL in a platform trial.

NCT ID: NCT04883437 Recruiting - Clinical trials for Mantle Cell Lymphoma

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Start date: September 3, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non-Hodgkin lymphoma for which the patient has not received treatment in the past (previously untreated). Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Giving acalabrutinib and obinutuzumab may kill more cancer cells.

NCT ID: NCT04870853 Recruiting - Clinical trials for Refractory Diffuse Large B-Cell Lymphoma

Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy

Start date: April 2, 2020
Phase:
Study type: Observational

This study characterizes cardiac events following standard of care chimeric antigen receptor T cell therapy in patients with aggressive B-Cell Lymphoma that has come back (relapsed) or does not respond to treatment (refractory). The results from this study may allow a description of these events, their managements and outcome.

NCT ID: NCT04849351 Recruiting - Follicular Lymphoma Clinical Trials

Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Start date: April 14, 2021
Phase: Phase 2
Study type: Interventional

A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL)

NCT ID: NCT04842318 Recruiting - Follicular Lymphoma Clinical Trials

Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study

Start date: March 1, 2021
Phase: Phase 4
Study type: Interventional

This multi-center clinical study will evaluate the efficacy of Rituximab maintenance treatment of newly diagnosed follicular lymphoma after induction therapy of BR, RCHOP or R2.

NCT ID: NCT04834024 Recruiting - Clinical trials for Follicular Lymphoma and Marginal Zone Lymphoma

MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma

Start date: June 2, 2021
Phase: Phase 3
Study type: Interventional

This phase III trial aims to compare the efficacy and safety of MIL62 combined lenalidomide and lenalidomide alone to treat patient diagnosed with Follicular Lymphoma (FL) and refractory to rituximab. The study randomized patients with a 1:1 ratio to receive either MIL62 plus lenalidomide or lenalidomide.